Article
Genetics & Heredity
Wuping Yang, Lei Li, Kenan Zhang, Kaifang Ma, Yanqing Gong, Jingcheng Zhou, Kan Gong
Summary: The study identified the clinical roles of CLDN10 in clear cell renal cell carcinoma (ccRCC), showing that reduced expression of CLDN10 is associated with metastasis and poor prognosis, while elevated expression is independently correlated with longer overall survival and disease-free survival. Furthermore, CLDN10 expression is negatively associated with DNA methylation levels and immune cell infiltration.
Article
Pharmacology & Pharmacy
Ganggang Wang, Zheng Wang, Haiquan Lu, Zhiqun Zhao, Liqiang Guo, Feng Kong, Aizhen Wang, Shengtian Zhao
Summary: FRAS1/FREM family members showed significantly decreased expression in KIRC tissues, which was associated with advanced clinicopathological parameters and poor prognosis. They could potentially exert anti-tumor effects by regulating immune infiltrating cells and participating in oncogenic signaling pathways and metabolic pathways. High expression of FRAS1 and FREM2 could serve as reliable predictors of targeted therapeutic drug response.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Oncology
Javier C. Angulo, Claudia Manini, Jose I. Lopez, Angel Pueyo, Begona Colas, Santiago Ropero
Summary: This review examines the accumulated evidence on the role of epigenetic markers in prognosis and treatments for clear cell renal cell carcinoma (ccRCC). Several epigenetic markers show promise for clinical use but require further validation. The development of epigenetic therapies, either alone or in combination with other treatments, is still in early stages and holds potential for improving the diagnosis and treatment of ccRCC.
Article
Cell Biology
Wenqing Lu, Xiaofang Che, Xiujuan Qu, Chunlei Zheng, Xianghong Yang, Bowen Bao, Zhi Li, Duo Wang, Yue Jin, Yizhe Wang, Jiawen Xiao, Jianfei Qi, Yunpeng Liu
Summary: This study comprehensively analyzed the role of succinylation regulators in ccRCC and suggested their specific and critical impact on tumor prognosis. By clustering patients based on the expression patterns of regulators, distinct clusters with different survival outcomes and clinicopathological features were identified, indicating their potential mechanisms in promoting malignant progression. The study provided new insights into the understanding of succinylation modification and its clinical implications in ccRCC treatments.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Zhixian Chen, Liang Wang, Jian Shi, Wen Xiao, Changfei Yuan, Xiangui Meng, Hailong Ruan, Zhiyong Xiong, Xiaoping Zhang
Summary: This study aimed to investigate the diagnostic and prognostic value of NCOA2 in clear cell renal cell carcinoma (ccRCC) based on its expression and methylation. The results showed that NCOA2 was lowly expressed in ccRCC tissue and was associated with PD-1/PD-L1 expression and infiltration of other immune cells. The findings suggest that NCOA2 has the potential to serve as a novel biomarker for predicting prognosis and a therapeutic target in late-stage ccRCC patients.
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
(2023)
Article
Oncology
S. C. Joosten, S. N. O. Odeh, A. Koch, N. Buekers, M. J. B. Aarts, M. M. L. L. Baldewijns, L. Van Neste, S. van Kuijk, L. J. Schouten, P. A. van den Brandt, V. C. Tjan-Heijnen, M. van Engeland, K. M. Smits
Summary: This study compared potential prognostic methylation markers for ccRCC and identified five methylation markers that potentially show prognostic value in addition to currently known clinicopathological factors. The prognostic biomarker model performed better than the clinical model in predicting outcomes, but had limited added value in a separate patient cohort.
CLINICAL EPIGENETICS
(2021)
Article
Cell Biology
Zhenhao Zeng, Zhicheng Zhang, Xiaofeng Cheng, Heng Yang, Binbin Gong, Xiaochen Zhou, Cheng Zhang, Xinyi Wang, Gongxian Wang
Summary: In this study, it was found that RAB17 is low-expressed in KIRC tissues. The downregulation of RAB17 expression is correlated with unfavorable clinicopathological characteristics and a worse prognosis in KIRC. Additionally, RAB17 is closely associated with immune infiltration. In vitro, silencing of RAB17 promotes KIRC cell migration.
CELLULAR SIGNALLING
(2023)
Article
Cell Biology
Fan Zhang, Junyu Lin, Dechao Feng, Jiayu Liang, Yiping Lu, Zhihong Liu, Xianding Wang
Summary: This study explored the correlation between cuprotosis and clear cell renal cell carcinoma (ccRCC) and developed a cuprotosis-related signature to predict the prognosis of patients with ccRCC. The signature risk score was significantly associated with tumor stage, histological grade, and immune cell infiltrates in ccRCC.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Cell Biology
Xuejie Yang, Cheng Mei, Hui Nie, Jianhua Zhou, Chunlin Ou, Xiaoyun He
Summary: An integrated study using multiple databases was conducted to investigate the diagnostic and prognostic biomarkers of kidney renal clear cell carcinoma (KIRC). The GATA family members were found to have potential as prognostic biomarkers and therapeutic targets for KIRC. The expression profiles of GATA2/3/6 were significantly lower in KIRC samples compared to normal samples, and their levels were closely related to KIRC's pathological grades, clinical stages, and lymph node metastases.
Article
Biotechnology & Applied Microbiology
W. Liang, S. H. Chen, G. L. Yang, J. Y. Feng, Q. Ling, B. Wu, H. B. Yan, J. W. Cheng
Summary: This study demonstrates that zinc-finger protein 677 (ZNF677) acts as a tumor suppressor gene in clear cell renal cell carcinoma (ccRCC), inhibiting tumor cell proliferation and invasion, inducing apoptosis. Low expression of ZNF677 is associated with shorter overall survival. High expression of ZNF677 can be considered as a favorable prognostic indicator for ccRCC.
Article
Genetics & Heredity
You Zuo, Shuai Fu, Zhongwei Zhao, Zeyan Li, Yijian Wu, Tienan Qi, Jianguo Zheng, Qinglong Du, Zhonghua Xu, Nengwang Yu
Summary: This study constructed a sarcomatoid-associated gene risk index (SAGRI) to predict the prognosis of renal cell carcinoma and found that SAGRI has a high predictive power. The study also suggested that the SAGRI-HIGH subgroup may benefit from immunotherapy.
FRONTIERS IN GENETICS
(2022)
Article
Biotechnology & Applied Microbiology
Qiong Deng, Ye Du, Zhu Wang, Yeda Chen, Jieyan Wang, Hui Liang, Du Zhang
Summary: This study aimed to establish a DNAm-driven gene-based prognostic model for ccRCC. RRBS was performed on ccRCC patients' DNA extracts to screen candidate CpG sites. The study identified the role of hypermethylation in ccRCC and discovered potential biomarkers for early diagnosis and prognosis evaluation.
Article
Biotechnology & Applied Microbiology
Zuhu Yu, Chong Lu, Bin Lu, Hong Gao, Rongfang Liang, Wuxing Xiang
Summary: This study identified necroptosis-related microRNAs (miRNAs) associated with the prognosis of clear cell renal cell carcinoma (ccRCC), and developed a prognostic signature to predict overall survival in ccRCC patients. The targeted genes of these miRNAs were predicted using miRNA databases, and their functional and pathway associations with ccRCC prognosis were investigated. The differential expression of the three miRNAs in the signature was validated in ccRCC tissues.
Article
Oncology
Olga Katzendorn, Inga Peters, Natalia Dubrowinskaja, Hossein Tezval, Pouriya Faraj Tabrizi, Christoph A. von Klot, Joerg Hennenlotter, Marcel Lafos, Markus A. Kuczyk, Juergen Serth
Summary: Our study revealed a significant association between TACSTD2 methylation and disease progression and clinical course of RCC, indicating a potential role of this gene in the development of RCC.
Article
Oncology
Raimonda Kubiliute, Kristina Zukauskaite, Algirdas Zalimas, Albertas Ulys, Rasa Sabaliauskaite, Arnas Bakavicius, Arunas Zelvys, Feliksas Jankevicius, Sonata Jarmalaite
Summary: This study identified novel DNA methylation biomarkers for ccRCC with potential clinical applications for non-invasive urine-based ccRCC detection and follow-up.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Hematology
Maysaa Abdulla, Peter Hollander, Tatjana Pandzic, Larry Mansouri, Susanne Bram Ednersson, Per-Ola Andersson, Magnus Hultdin, Maja Fors, Martin Erlanson, Sofie Degerman, Helga Munch Petersen, Fazila Asmar, Kirsten Gronbaek, Gunilla Enblad, Lucia Cavelier, Richard Rosenquist, Rose-Marie Amini
AMERICAN JOURNAL OF HEMATOLOGY
(2020)
Article
Pediatrics
Ewa Henckel, Mattias Landfors, Zahra Haider, Paraskevi Kosma, Magnus Hultdin, Sofie Degerman, Kajsa Bohlin
PEDIATRIC RESEARCH
(2020)
Article
Oncology
Zahra Haider, Mattias Landfors, Irina Golovleva, Martin Erlanson, Kjeld Schmiegelow, Trond Flaegstad, Jukka Kanerva, Ulrika Noren-Nystrom, Magnus Hultdin, Sofie Degerman
BLOOD CANCER JOURNAL
(2020)
Article
Geriatrics & Gerontology
Sara Pudas, Maria Josefsson, Annelie Nordin Adolfsson, Mattias Landfors, Karolina Kauppi, Line Marie Veng-Taasti, Magnus Hultdin, Rolf Adolfsson, Sofie Degerman
Summary: Shorter baseline LTL is associated with subsequent memory decline, but intra-individual changes in LTL may not be as informative of cognitive outcomes in aging. Long-term longitudinal evaluation of outcomes in biomarker research is essential.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
(2021)
Article
Pediatrics
Ewa Henckel, Anna James, Jon R. Konradsen, Bjorn Nordlund, Malin Kjellberg, Eva Berggren-Brostrom, Gunilla Hedlin, Sofie Degerman, Kajsa Bohlin
Summary: This study found that children born extremely preterm with a history of BPD had significantly higher YKL-40 levels compared to children with asthma at 10 years old. High levels of YKL-40 and short RTLs were associated with the need for ventilatory support for more than 1 month in the neonatal period, suggesting these markers may predict the long-term consequences of BPD in children with a history of prematurity.
Article
Oncology
Erik Bovinder Ylitalo, Elin Thysell, Mattias Landfors, Maria Brattsand, Emma Jernberg, Sead Crnalic, Anders Widmark, Magnus Hultdin, Anders Bergh, Sofie Degerman, Pernilla Wikstrom
Summary: Integrated epigenome and transcriptome analysis identified pronounced hypermethylation in malignant compared to non-malignant areas of localized prostate tumors. Metastases showed an overall hypomethylation in relation to primary PC, including CpGs in the AR promoter accompanied with induction of AR mRNA levels. We identified a Methylation Classifier for Androgen receptor activity (MCA) signature, which separated metastases into two clusters (MCA positive/negative) related to tumor characteristics and patient prognosis.
CLINICAL EPIGENETICS
(2021)
Article
Oncology
Wendy Yi-Ying Wu, Zahra Haider, Xiaoshuang Feng, Alicia K. Heath, Anne Tjonneland, Antonio Agudo, Giovanna Masala, Hilary A. Robbins, Maria-Jose Huerta, Marcela Guevara, Matthias B. Schulze, Miguel Rodriguez-Barranco, Paolo Vineis, Rosario Tumino, Rudolf Kaaks, Renee T. Fortner, Sabina Sieri, Salvatore Panico, Therese Haugdahl Nost, Torkjel M. Sandanger, Tonje Braaten, Mattias Johansson, Beatrice Melin, Mikael Johansson
Summary: The study evaluated the risk-discriminatory performance of the EarlyCDT-Lung test in ever-smokers and found that it is not effective in identifying high-risk individuals for lung cancer screening.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Lien Provez, Tom Putteman, Mattias Landfors, Juliette Roels, Lindy Reunes, Sara T'Sas, Wouter Van Loocke, Beatrice Lintermans, Stien De Coninck, Morgan Thenoz, Wouter Sleeckx, Natalia Mackowska-Maslak, Tom Taghon, Marc R. Mansour, Nadine Farah, Koen Norga, Peter Vandenberghe, Rishi S. Kotecha, Steven Goossens, Sofie Degerman, Renate De Smedt, Pieter Van Vlierberghe
Summary: T-cell lymphoblastic lymphoma (T-LBL) is a rare and aggressive lymphatic cancer, often diagnosed in teenagers and young adults. Patients are usually treated with chemotherapy or hematopoietic stem cell transplantation, but relapse still occurs. Decitabine, a DNA hypomethylating agent, shows potential as a less toxic therapy. This study provides preclinical proof of the use of decitabine as a therapeutic agent in T-LBL.
Article
Oncology
Xiaoshuang Feng, Wendy Yi-Ying Wu, Justina Ucheojor Onwuka, Zahra Haider, Karine Alcala, Karl Smith-Byrne, Hana Zahed, Florence Guida, Renwei Wang, Julie K. Bassett, Victoria Stevens, Ying Wang, Stephanie Weinstein, Neal D. Freedman, Chu Chen, Lesley Tinker, Therese Haugdahl Nost, Woon-Puay Koh, David Muller, Sandra M. Colorado-Yohar, Rosario Tumino, Rayjean J. Hung, Christopher Amos, Xihong Lin, Xuehong Zhang, Alan A. Arslan, Maria-Jose Sanchez, Elin Pettersen Sorgjerd, Gianluca Severi, Kristian Hveem, Paul Brennan, Arnulf Langhammer, Roger L. Milne, Jian-Min Yuan, Beatrice Melin, Mikael Johansson, Hilary A. Robbins, Mattias Johansson
Summary: This study aimed to develop a proteomics-based risk model for lung cancer and compare its performance with a smoking-based risk model and a commercially available autoantibody biomarker test. We conducted a case-control study in 6 prospective cohorts, involving 624 lung cancer participants and 624 smoking-matched cancer free participants. The protein-based risk model showed promise in predicting incident lung cancer and outperformed the standard risk prediction model and the commercialized EarlyCDT-Lung.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Article
Oncology
Karin Wallander, Zahra Haider, Ashwini Jeggari, Hassan Foroughi-Asl, Anna Gellerbring, Anna Lyander, Athithyan Chozhan, Ollanta Cuba Gyllensten, Moa Haegglund, Valtteri Wirta, Magnus Nordenskjoeld, Mats Lindblad, Emma Tham
Summary: In this study, the analysis of cell-free DNA as a prognostic cancer biomarker was evaluated for gastric and oesophageal cancer. The detection of cell-free DNA from the cancer was associated with a worse prognosis. The method of analysis, including tissue biopsy or analysis of blood cells, was found to be important for improving detection.
Article
Oncology
Zahra Haider, Tove Wasterlid, Linn Deleskog Spangberg, Leily Rabbani, Cecilia Jylha, Birna Thorvaldsdottir, Aron Skaftason, Hero Nikdin Awier, Aleksandra Krstic, Anna Gellerbring, Anna Lyander, Moa Hagglund, Ashwini Jeggari, Georgios Rassidakis, Kristina Sonnevi, Birgitta Sander, Richard Rosenquist, Emma Tham, Karin E. Smedby
Summary: This study demonstrates the clinical potential of using whole-genome sequencing to analyze lymphoma at diagnosis, which facilitates the detection of measurable residual disease during treatment and follow-up. The results show that this method can detect lymphoma relapse earlier than clinical manifestation.
FRONTIERS IN ONCOLOGY
(2023)
Letter
Oncology
K. E. Smedby, T. Waesterlid, E. Tham, Z. Haider, J. Joelsson, B. Thorvaldsdottir, A. Krstic, B. E. Wahlin, H. Foroughi-Asl, C. Karlsson, S. Eloranta, L. Saft, M. Palma, A. Kwiecinska, L. Hansson, A. Osterborg, V. Wirta, G. Rassidakis, B. Sander, K. Sonnevi, R. Rosenquist
Article
Oncology
Juliette Roels, Morgan Thenoz, Mattias Landfors, Stien De Coninck, Lisa Demoen, Lien Provez, Anna Kuchmiy, Steven Strubbe, Lindy Reunes, Tim Pieters, Filip Matthijssens, Wouter Van Loocke, Busra Erarslan-Uysal, Paulina Richter-Pechanska, Ken Declerck, Tim Lammens, Barbara De Moerloose, Dieter Deforce, Filip Van Nieuwerburgh, Laurence C. Cheung, Rishi S. Kotecha, Marc R. Mansour, Bart Ghesquiere, Guy Van Camp, Wim Vanden Berghe, Jerzy R. Kowalczyk, Tomasz Szczepanski, Utpal P. Dave, Andreas E. Kulozik, Steven Goossens, David J. Curtis, Tom Taghon, Malgorzata Dawidowska, Sofie Degerman, Pieter Van Vlierberghe
BLOOD CANCER DISCOVERY
(2020)